A Rapid Immunoassay for the Simultaneous Direct Detection and Differential Diagnosis of SARS-CoV-2, Influenza Type A and Type B Antigen
- Sensitivity and Specificity
- COVID-19 - PPA 94%, NPA 100%
- Flu A - PPA 89.2%, NPA 99.4%
- Flu B - PPA 86.4%, NPA 99% - FDA Emergency Use Authorization (EUA)
- Visually read in 15 minutes
- Flocked nasopharyngeal swab for superior specimen collection and patient comfort
CPT COVID-19: 87811QW
FLU A: 87804QW
FLU B: 87804QW-59
